A core component of our corporate strategy is to develop productive partnerships and collaborations to systematically identify platforms and product candidates for which human proof of concept exists in the intended indication, for either the target or the compound, and for which biomarkers are available to measure therapeutic response.

Our strategy for targeting conditions

We target conditions where we believe current treatments fail to address unmet medical needs, and where we can apply clinical strategies to increase efficacy signal detection. These strategies include using personalized therapeutic approaches and placebo mitigation techniques to facilitate regulatory approval for our product candidates.

Successful partnerships are critical for us to meet our objectives and as such, we are seeking out-licensing partnerships and in-licensing opportunities.

Contact us to learn more about partnership opportunities.